Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C

Liver International

Volumn 27, Issue 8, 2007, Pages 1111-1118

  Carr, Catherine ^a   Blaine Hollinger, F ^b   Yoffe, Boris ^b   Wakil, Adil ^a   Phillips, Jason ^a   Bzowej, Natalie ^a   Leung, Janet ^a   Mirro, Katherine ^a   Poordad, Fred ^c   Moore, Dan H ^a   Gish, Robert G ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antiviral agents; Chronic hepatitis C; Chronic liver disease; Human; Induction; Interferon ; Pegylated interferon; Ribavirin; Sustained virologic response

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERONS; LIVER; MALE; MIDDLE AGED; PATIENT SELECTION; RIBAVIRIN; RNA, VIRAL; SEX FACTORS; TIME FACTORS; TREATMENT FAILURE; UNITED STATES; VIRAL LOAD;

EID: 34548606126     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01535.x     Document Type: Article

References (18)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
2. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: Patient and treatment considerations. Clin Gastroenterol Hepatol 2005; 3: 311-8.
3. Di Bisceglie AM. Natural history of hepatitis C: Its impact on clinical management. Hepatology 2000; 31: 1014-8.
4. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis. A national heart, lung, and blood institute collaborative study. Hepatology 2001; 33: 455-63.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
7. Shiffman ML. Retreatment of chronic hepatitis C virus infection in patients who failed to achieve sustained virologic response. Minerva Gastroenterol Dietol 2004; 50: 37-49.
8. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 2453-2462.
9. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. J Hepatol 2006; 44: 291-301.
10. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin versus interferon alone in the re-treatment of chronic hepatitis C previously non-responsive to interferon: A meta-analysis of randomized trials. JAMA 2001; 285: 193-9.
11. Sostegni R, Ghisetti V, Pittaluga F, et al. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 1998; 28: 341-6.
12. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon-alpha. Hepatology 1997; 26: 226-31.
13. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kDa)/ribavirin. J Hepatol 2005; 43: 425-33.
14. Hass HG, Kreysel C, Fischinger J, et al. High-dose interferon α-2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-α monotherapy. World J Gastroenterol 2005; 11: 5342-6.
15. Kaiser S, Hass H, Lutze B, et al. Higher susceptibility of peginterferon alfa-2a versus peginterferon alfa-2b nonresponder patients with chronic hepatitis C to retreatment with consensus interferon daily dosing and ribavirin. Abstract S1061. Digestive Diseases Week. 20-25 May 2006. Los Angeles, CA.
16. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
17. Berg C, Goncales FL Jr, Bernstein DE, et al. Re-treatment of chronic hepatitis C patients after relapse: Efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006; 13: 435-40.
18. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International hepatitis interventional therapy group. N Engl J Med 1998; 339: 1493-9.